These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17255743)

  • 1. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 2. Providing antiretroviral therapy for HIV infection.
    Steinbrook R
    N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164
    [No Abstract]   [Full Text] [Related]  

  • 3. Inequalities in health: access to treatment for HIV/AIDS.
    Giuliano M; Vella S
    Ann Ist Super Sanita; 2007; 43(4):313-6. PubMed ID: 18209264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to HIV drugs: are we changing the two world paradigm?
    Lazzarini Z
    Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
    [No Abstract]   [Full Text] [Related]  

  • 6. Sustaining treatment costs: who will pay?
    Zewdie D; De Cock K; Piot P
    AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
    [No Abstract]   [Full Text] [Related]  

  • 7. HAART--the need for strategically focused investments.
    Feachem R
    Bull World Health Organ; 2001; 79(12):1152-3. PubMed ID: 11842786
    [No Abstract]   [Full Text] [Related]  

  • 8. The human right to health, national courts, and access to HIV/AIDS treatment: a case study from Venezuela.
    Torres MA
    Chic J Int Law; 2002; 3(1):105-14. PubMed ID: 15709302
    [No Abstract]   [Full Text] [Related]  

  • 9. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The price of HIV treatment.
    Brinkman K
    Neth J Med; 2003 Dec; 61(12):391-2. PubMed ID: 15025413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplifying HIV therapeutics, and the global treatment of AIDS.
    Laurence J
    AIDS Read; 2003 Jan; 13(1):5-6. PubMed ID: 12569889
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 13. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
    Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing HIV treatment programs.
    Bautista-Arredondo S; Martz TE; Wirtz VJ; Bertozzi SM
    Curr Opin HIV AIDS; 2010 May; 5(3):232-6. PubMed ID: 20539079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costing universal access of highly active antiretroviral therapy in Benin.
    Hounton SH; Akonde A; Zannou DM; Bashi J; Meda N; Newlands D
    AIDS Care; 2008 May; 20(5):582-7. PubMed ID: 18484329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretrovirals in India.
    Pujari S
    Issues Med Ethics; 1998 Jan; 6(1):24-5. PubMed ID: 16267924
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.
    Moatti JP; N'Doye I; Hammer SM; Hale P; Kazatchkine M
    Nat Med; 2003 Dec; 9(12):1449-52. PubMed ID: 14647513
    [No Abstract]   [Full Text] [Related]  

  • 18. Approaches to rationing antiretroviral treatment: ethical and equity implications.
    Bennett S; Chanfreau C
    Bull World Health Organ; 2005 Jul; 83(7):541-7. PubMed ID: 16175829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The (political) economics of antiretroviral treatment in developing countries.
    Nattrass NJ
    Trends Microbiol; 2008 Dec; 16(12):574-9. PubMed ID: 18964022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries.
    Beck EJ; Santas XM; Delay PR
    AIDS; 2008 Jul; 22 Suppl 1():S75-85. PubMed ID: 18664958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.